Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial.
Ann OncolMay 19, 2026 (epub)
Clinical ResearchOncology (Medical)
M Dugo, C-S Huang, D Egle et al.
✦ AI-curated · Sources linked
In 30 seconds
The NeoTRIPaPDL1 trial, a randomized phase III study, evaluated 280 high-risk patients with triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy with or without atezolizumab. The study found that higher baseline proliferation and lower stromal programs correlated with increased pathologic complete response (pCR) rates, while early tumor cell absence in on-treatment biopsies strongly predicted pCR across both treatment arms.
Key findings
- Higher proliferation and lower stromal programs at baseline were linked to increased pCR rates in the CT/A arm.
- Absence of tumor cells in early on-treatment biopsies was a strong predictor of surgical pCR.
- Dynamic remodeling of the tumor microenvironment was observed, with immune-related programs becoming dominant correlates of response.
- Exploratory analyses suggested contributions of on-treatment immune activity and iron metabolism to treatment response.
Why it matters
Identifying predictive biomarkers for response to neoadjuvant chemoimmunotherapy in TNBC can enhance patient selection and treatment strategies, potentially improving outcomes in this challenging cancer subtype.